WHO Sounds Alert Over Critical Shortage of Obesity Injections

Under a tenth of individuals who could benefit from obesity jabs including Wegovy are able to get them, states the World Health Organization as it publishes its first advice on the drugs.

Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer availability to this class of drugs.

Based on forecasts, more than two billion could be living with obesity by 2030 without intervention.

"Our latest guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are major hurdles to widespread availability to the treatments that can help people shift substantial body mass, says the body.

GLP-1 Therapy Shortage

Despite the present best projected case, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, according to the WHO.

The advice urges governments and firms to expand availability, by measures including patent sharing.

Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.

The Way Obesity Jabs Operate

GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals eat less.

People usually begin shedding pounds after several weeks of commencing the regular doses.

Research points to people may put most of the weight back on after a year of halting the medication, as their typical food cravings resume.

To be above a healthy weight raises your risk for experiencing diseases, like diabetes, heart disease, brain attack, and some cancers.

Excess weight concerns individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the WHO.